Gilead Sciences: One-once Complera offers a welcome alternative to Atripla
This article was originally published in Scrip
Executive Summary
On August 10, 2011 Gilead Sciences announced US Food and Drug Administration (FDA) approval for its novel cross-class fixed-dose combination (FDC) Complera, making it the second one-pill once-daily regimen on the market for HIV treatment after Atripla.